In a report released Wednesday, the Biden administration called for increased transparency in healthcare transactions to better monitor the growing influence of private equity on care delivery.
Private equity poses ‘new and unique risks’ to healthcare, federal agencies warn Read More »
AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for sustainable success in 2025.
La inteligencia artificial (IA) está revolucionando la biomedicina, impactando en áreas clave como la interpretación de imágenes médicas y el análisis de grandes bases de datos de investigación. La IA está logrando avances importantes …
La Inteligencia Artificial y los datos falsos en biomedicina Read More »
With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration will likely understand why medicines should be treated differently.
The Rise of China Innovation in the Time of Trump Read More »
AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for sustainable success in 2025.
After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has publicly laid out its reasoning for rejecting Vanda Pharmaceuticals’ gastroparesis drug candidate tradipitant.
In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis talks to Dr. Peter Marks, Director, CBER about his thoughts on the future of cell and gene therapies.
A Conversation with Peter Marks: Insights into GenScript Biotech Forum 2025 Read More »
Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program that the HHS claims violates anti-kickback statutes.
HHS Says Vertex is ‘Grasping at Straws’ With Casgevy Fertility Suit Read More »
Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she will oversee BioNTech’s transition from a COVID-19 vaccine maker to an “end-to-end organizational oncology powerhouse.”
BioNTech Strives to Become Commercial ‘Powerhouse’ While Maintaining Humility Read More »
Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according to analysts from BMO Capital Markets.
Lilly’s I&I Push Gains Momentum With Omvoh Expansion Read More »
